Increased numbers of CD5+ B lymphocytes with a regulatory phenotype in spondylarthritis

Arthritis and Rheumatism

Volumn 64, Issue 6, 2012, Pages 1859-1868

  Cantaert, Tineke ^a   Doorenspleet, Marieke E ^a   Francosalinas, Gabriela ^a   Paramarta, Jaqueline E ^a   Klarenbeek, Paul L ^a   Tiersma, Yvonne ^a   Van Der Loos, Chris M ^a   De Vries, Niek ^a   Tak, Paul Peter ^a   Baeten, Dominique L ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 6;

ADULT; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; JOINT BIOPSY; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; MALE; MEMORY CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SOMATIC HYPERMUTATION; SPONDYLARTHRITIS;

ADULT; ANTIGENS, CD5; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES, REGULATORY; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; SPONDYLARTHRITIS; SYNOVIAL MEMBRANE;

EID: 84861820579     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34364     Document Type: Article

References (52)

1. Vandooren B, Tak PP, Baeten D,. Synovial and mucosal immunopathology in spondyloarthritis. Adv Exp Med Biol 2009; 649: 71-84.
2. Lories RJ, Baeten DL,. Differences in the pathophysiology between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009; 27: S10-4.
3. Cunnane G, Bresnihan B, FitzGerald O,. Immunohistologic analysis of peripheral joint disease in ankylosing spondylitis. Arthritis Rheum 1998; 41: 180-2.
4. Baeten D, Demetter P, Cuvelier C, Van den Bosch F, Kruithof E, Van Damme N, et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000; 59: 945-53.
5. Appel H, Kuhne M, Speikermann S, Ebhardt H, Grozdanovic Z, Kohler D, et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006; 54: 2845-51.
6. Canete JD, Santiago B, Cantaert T, Sanmarti R, Palacin A, Celis R, et al. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis 2007; 66: 720-6.
7. Cantaert T, Kolln J, Timmer T, van der Pouw Kraan TC, Vandooren B, Thurlings RM, et al. B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. J Immunol 2008; 181: 785-94.
8. Schroder AE, Sieper J, Berek C,. Antigen-dependent B cell differentiation in the synovial tissue of a patient with reactive arthritis. Mol Med 1997; 3: 260-72.
9. Voswinkel J, Weisgerber K, Pfreundschuh M, Gause A,. B lymphocyte involvement in ankylosing spondylitis: the heavy chain variable segment repertoire of B lymphocytes from germinal center-like foci in the synovial membrane indicates antigen selection. Arthritis Res 2001; 3: 189-95.
10. Shi S, Ciurli C, Cartman A, Pidoux I, Poole AR, Zhang Y,. Experimental immunity to the G1 domain of the proteoglycan versican induces spondylitis and sacroiliitis, of a kind seen in human spondylarthropathies. Arthritis Rheum 2003; 48: 2903-15.
11. Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010; 62: 1290-7.
12. Cantaert T, De Rycke L, Mavragani CP, Wijbrandts CA, Niewold TB, Niers T, et al. Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor α blockade. Ann Rheum Dis 2009; 68: 1022-9.
13. Mackay IR,. Clustering and commonalities among autoimmune diseases. J Autoimmun 2009; 33: 170-7.
14. Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C, et al. Immunomodulatory effects of anti-tumor necrosis factor α therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001; 44: 186-95.
15. Kruithof E, De Rycke L, Roth J, Mielants H, Van den Bosch F, De Keyser F, et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005; 52: 3898-909.
16. Baeten D, Kruithof E, Breban M, Tak PP,. Spondylarthritis in the absence of B lymphocytes. Arthritis Rheum 2008; 58: 730-3.
17. Nocturne G, Dougados M, Constantin A, Richez C, Sellam J, Simon A, et al. Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry. Ann Rheum Dis 2010; 69: 471-2.
18. Bettelli E, Baeten D, Jager A, Sobel RA, Kuchroo VK,. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 2006; 116: 2393-402.
19. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF,. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 2008; 118: 3420-30.
20. Mauri C, Gray D, Mushtag N, Londei M,. Prevention of arthritis by interleukin 10-producing B cells. J Exp Med 2003; 197: 489-501.
21. Carter N, Vasconcellos R, Rosser E, Tulone C, Munoz-Suano A, Kamanaka M, et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol 2011; 186: 5569-79.
22. Mizoguchi E, Mizoguchi A, Preffer FI, Bhan AK,. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int Immunol 2000; 12: 597-605.
23. Papadakis KA, Rosenbloom B, Targan SR,. Anti-CD20 chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease. Gastroenterology 2003; 124: 583.
24. Goetz M, Aterya R, Ghalibafian M, Galle PR, Neurath MF,. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 2007; 13: 1365-8.
25. El Fassi D, Nielsen CH, Kjeldsen J, Clemmensen O, Hegedus L,. Ulcerative colitis following B lymphocyte depletion with rituximab in a patients with Graves' disease. Gut 2008; 57: 714-5.
26. Rudwaleit M, Baeten D,. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2006; 20: 451-71.
27. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al the European Spondylarthropathy Study Group. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218-27.
28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
29. Baeten D, Van den Bosch F, Elewaut D, Stuer A, Veys EM, De Keyser F,. Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol 1999; 18: 434-41.
30. Klarenbeek PL, Tak PP, van Schaik BD, Zwinderman AH, Jakobs ME, Zhang Z, et al. Human T-cell memory consists mainly of unexpanded clones. Immunol Lett 2010; 133: 42-8.
31. Klarenbeek PL, de Hair MJ, Doorenspleet ME, van Schaik BD, Esveldt RE, van de Sande MG, et al. Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease. Ann Rheum Dis 2012. E-pub ahead of print.
32. + phenotype controls T cell-dependent inflammatory responses. Immunity 2008; 28: 639-50.
33. Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmitt C, Dalloul AH,. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood 2002; 100: 4537-43.
34. Youinou P, Jamin C, Lydard PM,. CD5 expression in human B-cell populations. Immunol Today 1999; 20: 312-6.
35. + pre-naïve B cell population. J Immunol 2009; 182: 4116-26.
36. hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010; 32: 129-40.
37. + B cells. J Exp Med 2008; 205: 2033-42.
38. Wu YC, Kipling D, Leong HS, Martin V, Ademokun AA, Dunn-Walters DK,. High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations. Blood 2010; 116: 1070-8.
39. Polese L, De Franchis G, Scarpa M, Sturniolo GC, Ruffolo C, Norberto L, et al. B1a lymphocytes in ulcerative colitis. Int J Colorectal Dis 2007; 22: 1005-11.
40. + B cells in inflammatory bowel disease. Scand J Gastroenterol 2009; 44: 172-9.
41. + B cells are decreased in peripheral blood of patients with Crohn's disease. Dig Dis Sci 1992; 37: 1390-5.
42. Bikah G, Carey J, Ciallella JR, Tarakhovsky A, Bondada S,. CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science 1996; 274: 1906-9.
43. Hippen KL, Tze LE, Behrens TW,. CD5 maintains tolerance in anergic B cells. J Exp Med 2000; 191; 883-90.
44. Garaud S, Le Dantec C, de Mendoza AR, Mageed RA, Youinou P, Renaudineau Y,. IL-10 production by B cells expressing CD5 with the alternative exon 1B. Ann N Y Acad Sci 2009; 1173: 280-5.
45. Hardy RR, Hayakawa K, Shimizu M, Yamasaki K, Kishimoto T,. Rheumatoid factor secretion from human Leu-1+ B cells. Science 1987; 236: 81-3.
46. + T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J Immunol 2007; 178: 3447-56.
47. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM,. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3: 944-50.
48. Garaud S, Le Dantec C, Jousse-Joulin S, Hantrotel-Saliou C, Saraux A, Mageed RA, et al. IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J Immunol 2009; 182: 5623-32.
49. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, et al, for the Immune Tolerance Network ST507 Study Group. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010; 120: 1836-47.
50. Pallier A, Hillion S, Danger R, Giral M, Racape M, Deguaque N, et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010; 78: 503-13.
51. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC,. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-20.
52. Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007; 56: 3044-56.